Evaluation of lung parenchyma, blood vessels, and peripheral blood lymphocytes as a potential source of acute phase reactants in patients with COPD

• Published in: International journal of chronic obstructive pulmonary disease Vol. 14; pp. 1323 - 1332
• Main Authors: Arellano-Orden, Elena, Calero, Carmen, López-Ramírez, Cecilia, Sánchez-López, Verónica, López-Villalobos, José Luis, Abad Arranz, María, Blanco-Orozco, Ana, Otero-Candelera, Remedios, López-Campos, José Luis
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.06.2019; Dove Medical Press Ltd; Dove; Dove Medical Press
• Subjects: Acute-Phase Proteins - analysis; Acute-Phase Proteins - immunology; Acute-Phase Reaction - blood; Acute-Phase Reaction - immunology; Analysis; arterial wall; Arteries; Biochemistry; Biomarkers; Blood vessels; C-reactive protein; Cancer research; Chronic obstructive lung disease; Chronic obstructive pulmonary disease; Comorbidity; Correlation of Data; EDTA; Enzymes; Female; Gene amplification; Gene expression; Genes; Humans; Immunohistochemistry; Inflammation; Liver; Lung - immunology; Lung - pathology; Lung cancer; Lymphocytes; Lymphocytes - immunology; Male; Medical research; Middle Aged; Original Research; parenchyma; Plasma; Proteins; Pulmonary arteries; Pulmonary Artery - immunology; Pulmonary Artery - pathology; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - pathology; serum amyloid A; Serum Amyloid A Protein - analysis; Spirometry; Spirometry - methods; Surgery; Veins & arteries; Spain; United Kingdom > UK; United States > US; parenchyma; C-reactive protein; arterial wall; inflammation; serum amyloid A; COPD
• DOI: 10.2147/COPD.S188567
• ISSN: 1178-2005; 1176-9106

Previous studies have shown that the arterial wall is a potential source of inflammatory markers in COPD. Here, we sought to compare the expression of acute phase reactants (APRs) in COPD patients and controls both at the local (pulmonary arteries and lung parenchyma) and systemic (peripheral blood leukocytes and plasma) compartments. Consecutive patients undergoing elective surgery for suspected primary lung cancer were eligible for the study. Patients were categorized either as COPD or control group based on the spirometry results. Pulmonary arteries and lung parenchyma sections, peripheral blood leukocytes, and plasma samples were obtained from all participants. Gene expression levels of C-reactive protein (CRP) and serum amyloid A (SAA1, SAA2, and SAA4) were evaluated in tissue samples and peripheral blood leukocytes by reverse transciption-PCR. Plasma CRP and SAA protein levels were measured by enzyme-linked immunosorbent assays. Proteins were evaluated in paraffin-embedded lung tissues by immunohistochemistry. A total of 40 patients with COPD and 62 controls were enrolled. We did not find significant differences in the gene expression between COPD and control group. Both CRP and SAA were overexpressed in the lung parenchyma compared with pulmonary arteries and peripheral blood leukocytes. The expression of SAA was significantly higher in the lung parenchyma than in the pulmonary artery (2-fold higher for SAA1 and SAA4, =0.015 and <0.001, respectively; 8-fold higher for SAA2, <0.001) and peripheral blood leukocytes (16-fold higher for SAA1, 439-fold higher for SAA2, and 5-fold higher for SAA4; <0.001). No correlation between plasma levels of inflammatory markers and their expression in the lung and peripheral blood leukocytes was observed. The expression of SAA in lung parenchyma is higher than in pulmonary artery and peripheral blood leukocytes. Notably, no associations were noted between lung expression of APRs and their circulating plasma levels, making the leakage of inflammatory proteins from the lung to the bloodstream unlikely. Based on these results, other potential sources of systemic inflammation in COPD (eg, the liver) need further scrutiny.